AGN

Big Pharma 1Q Earnings Roundup, Part II

by

Image Source: Paw Paw Companies mentioned: ABBV, AGN, BMY, AMGN, MRK, PFE. AbbVie (ABBV) Riding Humira to the End AbbVie’s performance in the first quarter of 2016 was nothing short of impressive, as the firm grew revenue by more than 18% on an as reported basis from the year-ago period. Humira (arthritis), the company’s headlining drug, sales increased nearly 15% as reported. New drug Imbruvica (leukemia) showed solid momentum in the quarter, and AbbVie received two approvals for the expansion of the Imbruvica as a first line therapy for chronic lymphocytic leukemia. The treatment is expected to play a key role in the future of the company, especially after its patent on Humira expires in December of this year. The … Read more

Teva Bounces After Strong First Quarter

by

Teva remains confident in its combination with Allergan Generics. Image source: Teva quarterly presentation. In July 2015, Best Ideas Newsletter portfolio holding Teva Pharmaceuticals (TEVA) announced it had agreed to acquire the generic drug portfolio of Allergan (AGN). It was expected that the firm would have to divest certain assets in order to clear the increasingly unpredictable US regulatory requirements, as is common with most acquisitions of its size. The deal was originally anticipated to be completed by the end of the first quarter of 2016, but it was announced March 15 that the transaction would be delayed. However, the process continues to take longer than foreseen, and Teva will have to sell more than the $1 billion in assets … Read more

Treasury Erects Iron Tax Curtain

by

Image Description/Source: Berlin Wall, 1963; Roger “If history is any guide, it would seem that tax lawmakers may want to think about the current political agenda’s similarities with respect to that of a “new” Berlin Wall–not one built of barbed wire but of prohibitive, restrictive tax laws–and whether such measures make sense in light of the events of the late 1980s.” – Valuentum Securities Late Monday April 4, the US Department of the Treasury launched an all-out attack on companies pursuing tax inversion deals and a technique called earnings stripping, the latter used as a means to minimize taxes after an inversion. Stating in no uncertain terms that such companies have only been successful due to the “benefits of being based … Read more

Growing Cautious on Teva Pharma

by

By Paul Tait and Kris Rosemann Since Teva Pharmaceuticals’ (TEVA) addition to the Best Ideas Newsletter portfolio in mid-2013 in the low-$40s, the company has been a strong performer, even though the past several months have been rather rough. Following difficult fourth-quarter results, we’re ready to take profits on the equity, and we plan to release an alert in the coming days, hopefully on market strength. Last year was a transformational year for Teva, or in the words of management, a year of “exceptional strategic, operational and financial performance.” The company has pursued a number of growth-driving acquisitions to offset headwinds mounting for its leading drug Copaxone, a top treatment for multiple sclerosis. The spotlight has shifted to the development … Read more

Discuss: Taxes and the Future of American Business

by

Image Source: Montgomery County Tax inversion deals are back on. And in a big way! Pharma giant Pfizer (PFE) and Allergan (AGN) announced the largest one, creating the biggest drug maker by revenue in the combination, one that will headquarter in Ireland for tax purposes. Do US tax holders truly believe they own the companies? Or are tax inversions a part of American freedom, championed on a global stage? What do you think? Comment below.

Catching Up With Some of Our Best Ideas

by

Teva Pharmaceutical (TEVA) Teva Pharmaceutical has been a key source of outperformance for the Best Ideas Newsletter portfolio since its addition in mid-2013, with its return excluding dividends currently at ~50%. We continue to think the generic pharma space offers significant opportunities for participants, and we like Teva’s global market position. We’re particularly big fans of its ‘first-to-file’ position in the US generics market, and we like its efforts to protect specialty drug Copaxone as the world’s leading treatment of multiple sclerosis. In the third quarter of 2015, foreign exchange rates took a slight toll on Teva’s reported revenue, which fell 5% from the year-ago period to $4.8 billion; on a constant currency basis, revenue increased 3%. Non-GAAP operating income … Read more

Big Pharma Earnings Continued…

by

Amgen (AMGN) Amgen’s second-quarter results, released July 30, were a sight to see. Total revenue advanced 4% versus the second quarter of last year thanks to strength in Enbrel (etanercept), Prolia (denosumab), Sensipar (cinacalcet), Kyprolis (carfilzomib) and XGEVA (denosumab). Adjusted operating income and adjusted earnings per share leapt 10% and 8% in the quarter thanks in part to the strong top-line performance but also solid adjusted operating margin improvement (~+2 percentage points). Free cash flow generation was also fantastic, with the firm hauling in $2.7 billion in the measure compared to $2.1 billion in the second quarter of 2014. Keys to the Quarter: Investors should keep an eye on its blockbuster Neulasta/NEUPOGEN performance, which faced sales pressure in the quarter, … Read more

Best Ideas Newsletter Holding Teva Surges!

by

On July 27, Teva Pharmaceuticals (TEVA) reported solid preliminary results for the second quarter of 2015. The firm is growing organically, and its fundamental strengths shone throughout its report. Revenue increased 6% in the period, after excluding the impact of currency headwinds and the sale of US OTC plants in the second quarter of 2014. Non-GAAP operating income grew 16% from the year-ago quarter to $1.6 billion, and non-GAAP earnings per share increased 15% to $1.43 in the period. Cash flow from operations advanced an impressive 41% to $1.5 billion in the second quarter, and free cash flow grew 51% to $1.3 billion in the period. The solid bottom line performance caused management to raise its earnings per share guidance … Read more

4 Opportunistic Stocks To Consider Buying in 2015

by

The Valuentum Buying Index (VBI) is a philosophy that considers the valuation of a company and the likelihood that a company’s stock will converge to a cash-flow derived fair value estimate. The VBI accepts the view that value is based on the sum of a company’s future expected discounted free cash flows and the excess cash on its balance sheet, while acknowledging that market participants must eventually agree with a firm’s underpricing (and buy the stock) in order to drive the stock’s price to fair value. An underpriced stock with no buying support is not poised to generate good returns, nor is an overpriced stock with good momentum as it will eventually succumb to panic selling once euphoria fades. Stocks … Read more

Big Pharma Round Up

by

Though much has been made about the patent cliff—shorthand for the expiration of the patents of a large number of drugs over a short period of time—we continue to believe that pipelines across much of the pharmaceutical space are flush with new drugs and therapies. Readers may have an individual favorite or two (or three) within the space (and there’s nothing wrong with that), but we think one of the best ways for investors to play the strong pipelines across the healthcare sector—and ongoing consolidation—is through the Health Care Select SPDR ETF (XLV), a holding in the Best Ideas portfolio. The ETF boasts Johnson & Johnson (JNJ), Pfizer (PFE), Merck (MRK), Gilead Sciences (GILD), and AbbVie (ABBV) as its top … Read more